Replimune Group Inc.(REPL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

REPL Replimune Group Inc.

Pre-Mkt 02-04 06:36:21 EST

7.38

+0.41

+5.81%

High7.46	Low6.94	Vol1.09M
Open7.03	D1 Closing6.98	Amplitude7.46%
Mkt Cap609.39M	Tradable Cap368.77M	Total Shares82.57M
T/O8.00M	T/O Rate2.18%	Tradable Shares49.97M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"REPL","market":"US","secType":"STK","nameCN":"Replimune Group Inc.","latestPrice":7.38,"timestamp":1770152400000,"preClose":6.975,"halted":0,"volume":1090110,"delay":0,"changeRate":0.058064516129032295,"floatShares":49968589,"shares":82572600,"eps":-3.467754,"marketStatus":"Pre-Mkt","change":0.405,"latestTime":"02-04 06:36:21 EST","open":7.03,"high":7.46,"low":6.94,"amount":7996961.93142,"amplitude":0.074552,"askPrice":8.46,"askSize":100,"bidPrice":6.98,"bidSize":3,"shortable":3,"etf":0,"ttmEps":-3.467754,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1770215400000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1532059200000,"exchange":"NASDAQ","adjPreClose":7.38,"postHourTrading":{"tag":"盘后","latestPrice":7.4098,"preClose":7.38,"latestTime":"19:25 EST","volume":13631,"amount":100646.445,"timestamp":1770164729584,"change":0.0298,"changeRate":0.004038,"amplitude":0.009485},"volumeRatio":1.302742917350205,"impliedVol":0.5995,"impliedVolPercentile":0.148},"requestUrl":"/m/hq/s/REPL","defaultTab":"news","newsList":[{"id":"2608333991","title":"Analysts Are Neutral on Top Healthcare Stocks: Replimune Group (REPL), ACADIA Pharmaceuticals (ACAD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2608333991","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608333991?lang=en_us&edition=fundamental","pubTime":"2026-02-04 10:41","pubTimestamp":1770172894,"startTime":"0","endTime":"0","summary":"Analysts fell to the sidelines weighing in on Replimune Group (REPL – Research Report) and ACADIA Pharmaceuticals (ACAD – Research Report) with neu...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-neutral-on-top-healthcare-stocks-replimune-group-repl-acadia-pharmaceuticals-acad-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-neutral-on-top-healthcare-stocks-replimune-group-repl-acadia-pharmaceuticals-acad-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLV","ACAD","HCSG","REPL"],"gpt_icon":0},{"id":"2608879066","title":"Replimune Group Q3 EPS $(0.77) Beats $(0.78) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2608879066","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608879066?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:16","pubTimestamp":1770124609,"startTime":"0","endTime":"0","summary":"Replimune Group (NASDAQ:REPL) reported quarterly losses of $(0.77) per share which beat the analyst consensus estimate of $(0.78) by 0.77 percent. This is a 2.53 percent increase over losses of $(0.79) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/02/50330135/replimune-group-q3-eps-0-77-beats-0-78-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REPL","BK4139"],"gpt_icon":0},{"id":"2608287917","title":"Replimune Amends Loan Agreement With Hercules Capital to Access Up to $155 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2608287917","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608287917?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:06","pubTimestamp":1770123977,"startTime":"0","endTime":"0","summary":"Replimune Group Inc. has amended its existing loan agreement with Hercules Capital, Inc. Under the revised terms, Replimune drew down $35 million upon closing, with the option to access an additional $120 million contingent on achieving post-approval milestones. The amendment also extends the debt repayment period from 2026 to 2027, providing Replimune with greater financial flexibility as it prepares for the potential commercialization of RP1. The company expects that this financing, alongside existing cash resources, will extend its cash runway into the first quarter of 2027.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Replimune Group Inc. published the original content used to generate this news brief via EDGAR, the Electronic Da","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDL8B4PKt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","REPL","HTGC","BK4135"],"gpt_icon":0},{"id":"2608787931","title":"Replimune meldet für die neun Monate bis Dezember 2025 einen Anstieg der Ausgaben für Forschung und Entwicklung auf 168,86 Mio. USD, plus 25 Prozent","url":"https://stock-news.laohu8.com/highlight/detail?id=2608787931","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608787931?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:01","pubTimestamp":1770123694,"startTime":"0","endTime":"0","summary":"Replimune meldet für die neun Monate bis Dezember 2025 einen Anstieg der Ausgaben für Forschung und Entwicklung auf 168,86 Mio. USD, plus 25 Prozent. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Replimune Group Inc. published the original content used to generate this news brief via GlobeNewswire  on February 03, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDLyBZ2V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","BK4585","IE00BKPKM429.USD","LU2210149790.SGD","LU2210150020.SGD","LU2095319765.USD","SG9999014021.USD","SG9999014013.SGD","BK4139","SG9999014005.SGD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","LU0314104364.USD","REPL","SG9999014039.USD","BK4588","NDAQ","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2608312879","title":"Replimune reports Q3 net loss of USD 70.93 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2608312879","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608312879?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:01","pubTimestamp":1770123694,"startTime":"0","endTime":"0","summary":"Replimune Group Inc. reported its unaudited financial results for the third quarter  and the first nine months  ended December 31, 2025. For Q3 2025, the company posted a net loss of USD 70.93 million, with net loss per share at USD 0.77. Research and development expenses for the quarter totaled USD 53.14 million, while selling, general and administrative expenses were USD 18.73 million. For the first nine months of fiscal 2025, Replimune reported a net loss of USD 240.72 million and net loss per share of USD 2.62. Research and development expenses for the period were USD 168.86 million, and selling, general and administrative expenses reached USD 77.72 million. As of December 31, 2025, cash, cash equivalents, and short-term investments stood at USD 269.14 million, with working capital at USD 230.27 million and total assets of USD 333.59 million. Total stockholders’ equity amounted to USD 210.54 million. The company noted ongoing activities regarding the FDA review of its Biologics Lic","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDL8nk06T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","LU2095319765.USD","SG9999014021.USD","IE00B64PRP62.GBP","SG9999014039.USD","LU0314104364.USD","IE00BKPKM429.USD","NDAQ","SG9999014013.SGD","LU2210150020.SGD","REPL","LU2210149790.SGD","IE00BGHQF748.EUR","BK4585","BK4112","IE00B3QW5Z07.USD","BK4588","BK4139"],"gpt_icon":0},{"id":"2608987930","title":"BRIEF-Replimune Group Q3 Net Income USD -70.93 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2608987930","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608987930?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:00","pubTimestamp":1770123646,"startTime":"0","endTime":"0","summary":"BRIEF-Replimune Group Q3 Net Income USD -70.93 Million\n\n\nFeb 03 (Reuters) - Replimune Group Q3 operating expenses USD 71.868 million.\n\nQ3 operating income USD -71.868 million\nQ3 basic EPS USD -0.77\nQ3 pretax profit USD -71.241 million\nQ3 cash & investments USD 269.1 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nPLX4B0CCA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","REPL"],"gpt_icon":0},{"id":"2608987607","title":"Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2608987607","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608987607?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:00","pubTimestamp":1770123607,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nTUA7KKD5B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","REPL"],"gpt_icon":0},{"id":"2608879879","title":"Replimune Group Q3 Cash & Investments USD 269.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2608879879","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608879879?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:00","pubTimestamp":1770123601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nPLX4B0CCA:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["REPL","BK4139"],"gpt_icon":0},{"id":"2608387622","title":"Replimune Group Q3 Basic EPS USD -0.77","url":"https://stock-news.laohu8.com/highlight/detail?id=2608387622","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608387622?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:00","pubTimestamp":1770123601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nPLX4B0CCA:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","REPL"],"gpt_icon":0},{"id":"2603564717","title":"Replimune Group Showcases Oncolytic Immunotherapy Advancements for Melanoma in New Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2603564717","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603564717?lang=en_us&edition=fundamental","pubTime":"2026-01-15 06:12","pubTimestamp":1768428765,"startTime":"0","endTime":"0","summary":"Replimune Group Inc. presented new data highlighting progress in its oncolytic immunotherapy platform, particularly in the treatment of melanoma. The company reported that approximately 1,000 patients have been treated across its RPx platform, with around 1,200 deep injections administered. The presentation included results from the IGNYTE study, which evaluated RP1 in combination with nivolumab in patients with anti-PD-1-failed melanoma. In a cohort of 140 patients, the overall response rate  was 33.6%, with a median duration of response of 24.8 months. Subgroup analyses showed consistent response rates, including a 26.2% ORR for patients previously treated with both anti-PD-1 and anti-CTLA-4 therapies, and a 25.0% ORR for those with advanced stage IVb-IVd disease. The company noted that its commercial team is prepared for a potential product launch, with logistics and operational strategies in place. You can access the full presentation through the link below.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nNDL2TnJTR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REPL","BK4139"],"gpt_icon":0},{"id":"2592911602","title":"Insiders At Replimune Group Sold US$766k In Stock, Alluding To Potential Weakness","url":"https://stock-news.laohu8.com/highlight/detail?id=2592911602","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592911602?lang=en_us&edition=fundamental","pubTime":"2025-12-17 20:27","pubTimestamp":1765974444,"startTime":"0","endTime":"0","summary":"Replimune Group, Inc. ( NASDAQ:REPL ) shareholders might have a reason to worry after multiple insiders sold their...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-repl/replimune-group/news/insiders-at-replimune-group-sold-us766k-in-stock-alluding-to","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-repl/replimune-group/news/insiders-at-replimune-group-sold-us766k-in-stock-alluding-to","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["REPL","BK4139"],"gpt_icon":0},{"id":"2590541989","title":"Replimune Group Director Kapil Dhingra Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2590541989","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590541989?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:31","pubTimestamp":1765488684,"startTime":"0","endTime":"0","summary":"Kapil Dhingra, Director at Replimune Group Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Replimune Group Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 11, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nNDL3j96VH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Replimune Group Director Kapil Dhingra Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REPL","BK4139"],"gpt_icon":0},{"id":"2589846830","title":"Replimune CEO Sushil Patel Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2589846830","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589846830?lang=en_us&edition=fundamental","pubTime":"2025-12-05 05:30","pubTimestamp":1764883851,"startTime":"0","endTime":"0","summary":"Sushil Patel, Chief Executive Officer and Director of Replimune Group Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Replimune Group Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 04, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDLbXpL3L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Replimune CEO Sushil Patel Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REPL","BK4139"],"gpt_icon":0},{"id":"2585167595","title":"Biotech Reawakens: Policy Clarity, Breakthrough Data and a Surge in M&A","url":"https://stock-news.laohu8.com/highlight/detail?id=2585167595","media":"LiveWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585167595?lang=en_us&edition=fundamental","pubTime":"2025-11-21 10:52","pubTimestamp":1763693545,"startTime":"0","endTime":"0","summary":"Sentiment toward pharmaceuticals—both emerging biotech and large-cap pharma—has shifted meaningfully since we last wrote at the end of FY25. Concerns around US tariff risk and “Most Favoured Nation”  pricing dominated headlines in April, but these issues have since been largely neutralised. As policy uncertainty has cleared, investors have returned their focus to fundamentals.From 30 June to 31 October 2025, the S&P Biotech Index rose more than 30%. Over the same period, HB Biotechnology portfolios delivered a 63% return, driven by multiple outstanding clinical readouts and two strategic takeovers of portfolio companies.Despite this global strength, the ASX healthcare sector has lagged , led by the ongoing weakness in ASX: CSL—once again underscoring the need for a global, diversified approach to healthcare investing.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/biotech-reawakens-policy-clarity-breakthrough-data-and-a-surge-in-m-a","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/biotech-reawakens-policy-clarity-breakthrough-data-and-a-surge-in-m-a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"livewire_stock","symbols":["LU0098860793.USD","MRK","LU1057294990.SGD","LU0289739699.SGD","USJW.SI","IE00BN8TJ469.HKD","LU1116320901.HKD","NVIW.SI","BK4505","LU1037948897.HKD","LU0265550359.USD","RNA","NVS","LU1934455277.USD","LU1934455194.USD","TSYW.SI","QLD","QURE","VIGL","LU0985320562.USD","PFE","REPL","SGXZ57979304.SGD","VRNA","LU2089984988.USD","USAW.SI","LU0861579265.USD","LU2023250504.SGD","LU1430594728.SGD","LU2324357040.USD","PSQ","BK4559","LU0238689110.USD","LU1929549753.HKD","LU0265550946.USD","MNQmain","TQQQ","CSL.AU","CELC","QID","IE00BSNM7G36.USD","SQQQ",".IXIC","IE00B19Z3B42.SGD","IE000M9KFDE8.USD","BK4532","SG9999014559.SGD","BK7067","NQmain"],"gpt_icon":1},{"id":"2584692672","title":"Replimune Group Q2 Net Income USD -83.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2584692672","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584692672?lang=en_us&edition=fundamental","pubTime":"2025-11-20 00:54","pubTimestamp":1763571272,"startTime":"0","endTime":"0","summary":"Nov 06 (Reuters) - Replimune Group Q2 operating expenses USD 84.291 million.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 06-NOV-202512:32:33.287 GMT","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD7D6mPx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REPL","BK4139"],"gpt_icon":0},{"id":"2581988758","title":"Replimune Group Inc  expected to post a loss of 75 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2581988758","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581988758?lang=en_us&edition=fundamental","pubTime":"2025-11-08 00:17","pubTimestamp":1762532225,"startTime":"0","endTime":"0","summary":"Replimune Group Inc  expected to post a loss of75cents a share - Earnings Preview Replimune Group Inc REPL.OQ REPL.O is expected to  show no change in quarterly revenue when it reports  results  for t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nL8N3WJ2B5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REPL","BK4139"],"gpt_icon":0},{"id":"1105330981","title":"Stock Track | Replimune Group Plummets 5% as Leerink Partners Slashes Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=1105330981","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105330981?lang=en_us&edition=fundamental","pubTime":"2025-11-07 23:59","pubTimestamp":1762531142,"startTime":"0","endTime":"0","summary":"Shares of Replimune Group Inc. (REPL) tumbled 5.06% in Friday's trading session following a significant price target cut by Leerink Partners. The biotech company, known for its work in oncolytic...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["REPL"],"gpt_icon":0},{"id":"2581886171","title":"Replimune Group Inc. publishes study on anti-PD-1-failed NMSC and MSI-H/dMMR solid tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2581886171","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581886171?lang=en_us&edition=fundamental","pubTime":"2025-11-07 22:10","pubTimestamp":1762524602,"startTime":"0","endTime":"0","summary":"Replimune Group Inc. published a document related to clinical research in oncology, specifically focusing on patients with anti-PD-1-failed non-melanoma skin cancer  and anti-PD-1-failed MSI-H/dMMR solid tumors. The document provides information about study design, response rates assessed by blinded independent central review using RECIST 1.1, and additional clinical trial details. The full document can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Replimune Group Inc. published the original content used to generate this news brief on November 07, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nNDL2TNdgG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","REPL"],"gpt_icon":0},{"id":"2581041624","title":"Replimune Group Inc : Files for Mixed Shelf Offering of up to $250 Mln- SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2581041624","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581041624?lang=en_us&edition=fundamental","pubTime":"2025-11-07 06:47","pubTimestamp":1762469226,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nFWN3WI1RO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["REPL","BK4139"],"gpt_icon":0},{"id":"2581095871","title":"Replimune Q2 net loss widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2581095871","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581095871?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:14","pubTimestamp":1762434844,"startTime":"0","endTime":"0","summary":"Replimune Q2 net loss widensOverviewReplimune fiscal Q2 net loss widens to $83.1 mln from $53.1 mln last yearCash position decreases to $323.6 mln from $483.8 mln as of March 31, 2025OutlookReplimune ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL1N3WI0QY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","REPL"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.replimune.com","stockEarnings":[{"period":"1week","weight":-0.0199},{"period":"1month","weight":-0.1708},{"period":"3month","weight":-0.1399},{"period":"6month","weight":0.3467},{"period":"1year","weight":-0.4617},{"period":"ytd","weight":-0.2407}],"compareEarnings":[{"period":"1week","weight":-0.0086},{"period":"1month","weight":0.0093},{"period":"3month","weight":0.0176},{"period":"6month","weight":0.0906},{"period":"1year","weight":0.1535},{"period":"ytd","weight":0.0112}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":-0.013766},{"month":2,"riseRate":0.375,"avgChangeRate":-0.055563},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.10067},{"month":4,"riseRate":0.571429,"avgChangeRate":0.118692},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.048711},{"month":6,"riseRate":0.857143,"avgChangeRate":0.223071},{"month":7,"riseRate":0.285714,"avgChangeRate":-0.088436},{"month":8,"riseRate":0.375,"avgChangeRate":0.023484},{"month":9,"riseRate":0.25,"avgChangeRate":-0.055352},{"month":10,"riseRate":0.625,"avgChangeRate":0.268092},{"month":11,"riseRate":0.625,"avgChangeRate":0.036282},{"month":12,"riseRate":0.25,"avgChangeRate":-0.087028}],"exchange":"NASDAQ","name":"Replimune Group Inc.","nameEN":"Replimune Group Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Replimune Group Inc.(REPL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Replimune Group Inc.(REPL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Replimune Group Inc.,REPL,Replimune Group Inc.股票,Replimune Group Inc.股票老虎,Replimune Group Inc.股票老虎国际,Replimune Group Inc.行情,Replimune Group Inc.股票行情,Replimune Group Inc.股价,Replimune Group Inc.股市,Replimune Group Inc.股票价格,Replimune Group Inc.股票交易,Replimune Group Inc.股票购买,Replimune Group Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Replimune Group Inc.(REPL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Replimune Group Inc.(REPL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}